A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients

Sabaawy, Dalia El; El-Haggar, Sahar Mohamed; El-Bahrawy, Hoda A.; Waked, Imam; El-Said, Hala

doi:10.1111/apm.12377

Cited by 5 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, a number of Egyptians started new DAA regimen (with/out IFN/RBV), including (a) ledipasvir-sofosbuvir for 12 weeks, (b) ombitasvir-paritaprevir-ritonavir plus ribavirin for 12 weeks, or (c) sofosbuvir plus ribavirin for 24 weeks [ 27 ], with the government covering expenses of 80% of patients, treating 5 million patients of an estimated 11 million infected people will still cost Egypt $4·5 billion of the $5.4 billion total health budget for 2016–17 [ 30 , 31 ]. A recent study indicated that Pegasys may be a superior choice of interferon therapy under low socioeconomic conditions [ 32 ]. Thus, in Egypt, PEG-IFN remains an integral part of treatment [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4

Rizk¹,

Hamdy²,

Al-Ansari³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

BackgroundEgypt has the highest prevalence of a difficult to treat chronic hepatitis C virus (HCV), genotype 4. Pretreatment factors could guide individualization of therapy which aids in treatment optimization and interleukin IL28B gene polymorphism has been shown to closely relate to HCV treatment response. Polymorphisms in genes encoding inhibitors of T-cell response, which have role in disease progression as Programmed Cell Death 1 (PD-1), and Cytotoxic T-Lymphocytes Antigen-4 (CTLA-4), could be candidate markers predicting treatment response.MethodsThis cohort study consisted of 200 chronic HCV genotype 4 infected patients treated with PegIFN α-2a and RBV in 2 hepatology centers. Genotyping of the polymorphisms in the IL28B gene region (rs12979860), PD1.3 (rs11568821) and CTLA-4 (rs231775) was performed on DNA collected from each patient using TaqMan® genotyping assay. Groups were classified according to response into sustained virological responders (SVR), or non-responders (NR). A multivariate logistic regression analysis was used to identify potential markers, host pretreatment clinical and viral predictive factors including viral load, insulin resistance, and alpha fetoprotein (AFP) related to treatment response.ResultsOur results showed that in a multivariate analyses IL28B C/C genotype was the most significant predictor for SVR (OR = 10.86; p<0.0001) followed by AFP (OR = 0.915; p = 0.001) then CTLA-4/G genotypes (OR = 1.948; p = 0.022). However, PD-1.3/A genotypes and platelets count were significantly related to response in univariate analysis only (OR = 1.973; p = 0.023; OR = 1.007; p = 0.009 respectively).ConclusionIL28B SNP, AFP level, and CTLA-4 SNP could be used in conjunction to predict treatment response in HCV genotype 4 infected Egyptian patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4

Rizk¹,

Hamdy²,

Al-Ansari³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The peginterferon αA2 the patient was given on day 8 might have influenced his plasma interferon-α levels ( 6 ). However, a previous study also showed increased levels of interferon-α in a patient who survived MERS-CoV infection but not in a person who died of MERS ( 7 ).…”

mentioning

confidence: 99%

Characteristics of Traveler with Middle East Respiratory Syndrome, China, 2015

Guan¹,

Mok²,

Chen³

et al. 2015

Emerg. Infect. Dis.

View full text Add to dashboard Cite

“…Several articles have claimed that PegIFN-α-2a provides a better outcome than PegIFNα-2b [8][9][10], whereas many others report no difference in outcomes [11][12][13]. Although the relative efficacies of different forms of PegIFN-α are still debated, the results in current study reveal that neither SVR rate nor the variation of mental health status, differed between patients who were treated with PegIFN-α-2a (Group A) and those who were treated with PegIFN-α-2b (Group B).…”

Section: Researchmentioning

confidence: 99%

“…Differences between these two PegIFN-α preparation include molecular weight, subtype of human IFN-α, pharmacokinetic profile (especially half-life) and pharmacodynamic gap [6,54,55]. PegIFN-α-2a is a long-acting interferon; is monopegylated with a 40kDa branched PEG moiety, and comprises four major positional isomers that involve Lys31, Lys121, Lys131, and Lys134 of interferon-α-2a [8][9][10]. We hypothesize that the unique pharmacological profile of PegIFN-α-2a may be related to the increase in serum levels of cytokines at week 24; however, the mechanism by PegIFN-α-2a and -2b differently alter pro-inflammatory cytokine levels warrants further study.…”

Section: Antiviral Treatment Pro-inflammatory Cytokines and Bdnfmentioning

confidence: 99%

See 1 more Smart Citation

Mental health, pro-inflammatory cytokines, and brain derived neurotrophic factor in patients undergoing treatment for hepatitis C: comparison between peginterferon-alpha-2a and peginterferon-alpha-2b

Wang¹,

Chen²,

Chien³

et al. 2017

Neuropsychiatry

View full text Add to dashboard Cite

This study examines potential differences in the mental health, pro-inflammatory cytokines and brain-derived neurotrophic factor (BDNF) of patients with hepatitis C virus (HCV) infection who underwent antiviral treatment with peginterferon-alpha-2a (PegIFN-α-2a) and peginterferon-alpha-2b (PegIFN-α-2b). Methods: In a 24 week non-randomized longitudinal study, 22 patients with HCV were treated with PegIFN-α-2a plus ribavirin (Group A), and 12 patients were treated with PegIFN-α-2b plus ribavirin (Group B). All patients were assessed on the Hospital Anxiety and Depression Scale (HADS), the Short-form Health-related Quality of Life (SF-36) questionnaire, and their serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β) and BDNF were compared at baseline and weeks 4, 12 and 24. Results: During the 24-week antiviral treatment, Group A and Group B exhibited similar rates of sustained virological response, increased depression levels, decreased scores of physical component summary (PCS) of the SF-36 and reduced serum BDNF levels. However, increased serum levels of IL-6, TNF-α, and IL-1β were observed only in Group A at the 24 th week. During the treatment period, the depression scores and PCS scores of the SF-36 were positively correlated with IL-6, TNF-α and IL-1β levels, and negatively correlated with BDNF levels. Anxiety scores of the HADS were positively correlated with TNF-α and IL-1β levels. Conclusion: This investigation provides insight into the differential effects of various peginterferon-alpha During antiviral treatment, IFN-α activates proinflammatory cytokines and contributes to the development of depressive symptoms [31]. A clinical study found that serum levels of BDNF declined in HCV patients who were undergoing 24 weeks of IFN-α treatment. Accompanying increased levels of pro-inflammatory cytokines were correlated with the development of depressive symptoms [32]. Some investigations have also suggested that IFN-induced depression is accompanied by immune activation and the

show abstract

A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients

Cited by 5 publications

References 31 publications

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4

Characteristics of Traveler with Middle East Respiratory Syndrome, China, 2015

Mental health, pro-inflammatory cytokines, and brain derived neurotrophic factor in patients undergoing treatment for hepatitis C: comparison between peginterferon-alpha-2a and peginterferon-alpha-2b

Contact Info

Product

Resources

About